Now Accepting New Patients!
Meet Dr. Kambiz Shetabi
Dr. Kambiz Shetabi is a board-certified cardiologist who brings compassion and exceptional skills to interventional cardiology at San Diego Cardiac Center. During his education at Aurora Health Care in Milwaukee, he was honored to be selected to serve as Chief Resident and Chief Fellow of Interventional Cardiology. In addition to English, Dr. Shetabi is also fluent in Farsi, allowing him to connect with a diverse range of patients.
Dr. Shetabi's Specialties
Dr. Shetabi's expertise lies in the following:
- Diagnostic Cardiology
- Advanced Imaging
- Interventional Cardiology
- Structural Heart Conditions
Board Certifications
Dr. Shetabi has achieved the following board certifications:
- American Board of Interventional Cardiology
- American Board of Cardiovascular Disease
- American Board of Nuclear Cardiology
- American Board of Internal Medicine
Interventional Cardiology Focus
Interventional cardiology is a specialized field focusing on diagnosing and treating heart disease using minimally invasive techniques.
As an interventional cardiologist, Dr. Kambiz Shetabi provides expert care for patients with vascular and coronary artery disease and structural heart conditions. His expertise includes treating heart valve disorders, septal defects, and other abnormalities that affect the heart’s function. Through advanced procedures, Dr. Shetabi helps restore cardiovascular health with precision and innovation.
Publications
- Association Between Body Surface Area and Outcomes After Percutaneous Coronary Intervention.
- Contemporary Practice Pattern of Revascularization in a Large Tertiary Care Referral Center in Non‐ST Elevation Myocardial Infarction: A Propensity‐Matched 10‐Year Experience.
- Hypertrophic Cardiomyopathy with Aortic Dilation: A Novel Observation.
- Clinical Application of WHF-MOGE(S) Classification for Hypertrophic Cardiomyopathy
- Relationship of Cardiac Troponin to Systolic Global Longitudinal Strain in Hypertrophic Cardiomyopathy
- Clinical Outcomes After Drug-Eluting Stents Versus Coronary Artery Bypass Surgery in High Surgical Risk Patients With Left Main or Three-Vessel Coronary Artery Disease